Advertisement

Role of Bisphosphonates in Breast Cancer Therapy

  • Hadar Goldvaser
  • Eitan AmirEmail author
Breast Cancer (EA Comen, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Breast Cancer

Opinion statement

Bisphosphonates are utilized routinely in breast cancer. In metastatic disease with bone involvement, bisphosphonates prevent or delay skeletal-related events and can improve pain control. Different agents have shown benefit compared with placebo or no treatment. While in unselected patients, comparison between zoledronic acid and pamidronate did not show a significant difference, exploratory analyses showed that in patients with osteolytic lesions or hypercalcemia, zoledronic acid is superior to pamidronate. De-escalating treatment with zoledronic acid from every 4 to every 12 weeks has been shown to provide similar control of skeletal morbidity and may result in less toxicity and reduced cost. While available data support bisphosphonate treatment for 2 years in metastatic disease, typical treatment duration is influenced by performance status with treatment discontinued only once patients are not well enough to continue receiving systemic therapy or developed treatment-related adverse events. In early-stage breast cancer, individual trials of adjuvant bisphosphonates have reported inconsistent results. However, the Early Breast Cancer Trialists’ Collaborative Group showed that bisphosphonates significantly reduce distant recurrence, bone recurrence, and breast cancer mortality, an effect observed in postmenopausal women only. The relative benefit of bisphosphonates was not influenced by receptor status, tumor grade, nodal involvement, or administration of adjuvant chemotherapy. Current guidelines support consideration of adjuvant zoledronic acid or oral clodronate for 3–5 years in postmenopausal women with early-stage disease. Although bisphosphonates are tolerated well, serious adverse events, including osteonecrosis of the jaw and renal impairment, can occur, especially for higher dose density schedules utilized in metastatic disease. Decision to include bisphosphonates in the treatment plan should be based on the anticipated absolute benefit and potential for adverse effects. In some patients with both early-stage and metastatic disease, omission of bisphosphonates is reasonable as the potential benefit from this treatment is not likely to outweigh its risks.

Keywords

Bisphosphonate Bone-modifying agent Osteoclast inhibition Breast cancer Adjuvant Metastatic 

Notes

Compliance with Ethical Standards

Conflict of Interest

Hadar Goldvaser declares that she has no conflict of interest.

Eitan Amir has received compensation from Genentech/Roche for the provision of expert testimony and from Apobiologix Agendia and Myriad Genetics for service as a consultant.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Scheid V, Buzdar AU, Smith TL, Hortobagyi GN. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer. 1986;58(12):2589–93.CrossRefGoogle Scholar
  2. 2.
    Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97(12):2692–6.CrossRefGoogle Scholar
  3. 3.
    Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995;10(10):1478.CrossRefGoogle Scholar
  4. 4.
    Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998;16(6):2038–44.CrossRefGoogle Scholar
  5. 5.
    Theriault RL, Lipton A, Hortobagyi GN, Leff R, Glück S, Stewart JF, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol. 1999;17(3):846–54.CrossRefGoogle Scholar
  6. 6.
    Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11(1):59–65.CrossRefGoogle Scholar
  7. 7.
    Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer. 2004;90(6):1133–7.CrossRefGoogle Scholar
  8. 8.
    Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100(1):36–43.CrossRefGoogle Scholar
  9. 9.
    Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7(5):377–87.PubMedGoogle Scholar
  10. 10.
    Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19(2):558–67.CrossRefGoogle Scholar
  11. 11.
    Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol. 2014;15(1):114–22.CrossRefGoogle Scholar
  12. 12.
    Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132–9.CrossRefGoogle Scholar
  13. 13.
    Martin M, Bell R, Bourgeois H, et al. Bone-related complications and quality of life in advanced breast cancer: Results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res. 2012;18:4841–9.CrossRefGoogle Scholar
  14. 14.
    Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998;339(6):357–63.CrossRefGoogle Scholar
  15. 15.
    Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol. 2008;19(12):2007–11.CrossRefGoogle Scholar
  16. 16.
    Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res. 2006;8(2):R13.CrossRefGoogle Scholar
  17. 17.
    Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 2012;13(7):734–42.CrossRefGoogle Scholar
  18. 18.
    von Minckwitz G, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, et al. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol. 2013;31(28):3531–9.CrossRefGoogle Scholar
  19. 19.
    Kristensen B, Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Bjerregaard B, et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol. 2008;47(4):740–6.CrossRefGoogle Scholar
  20. 20.
    • Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol. 2014;15(9):997–1006 First randomized trial to identify the benefit of bisphosphonates in early-stage breast cancer as being limited to postmenopausal women. CrossRefGoogle Scholar
  21. 21.
    Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015;26(2):313–20.CrossRefGoogle Scholar
  22. 22.
    von Minckwitz G, Rezai M, Tesch H, Huober J, Gerber B, Zahm DM, et al. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - the Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). Eur J Cancer. 2016;64:12–21.CrossRefGoogle Scholar
  23. 23.
    Jani W, Friedl T, Fehm T, Mueller V, Lichtenegger W, Blohmer J, et al. Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: phase III data from the SUCCESS A study. Presented at the San Antonio Breast Cancer Symposium 2017, #GS01.Google Scholar
  24. 24.
    Gralow J, Barlow WE, Paterson AHG, et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient-stated preference for oral versus intravenous delivery. J Clin Oncol 32, 2014 (abstr 558).CrossRefGoogle Scholar
  25. 25.
    Gralow J, Barlow WE, Paterson AHG, et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology Study S0307. J Clin Oncol 33, 2015 (abstr 503).CrossRefGoogle Scholar
  26. 26.
    •• O’Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017;10:CD003474 Meta-analysis of randomized trials of bisphosphonates for both early-stage and metastatic breast cancer. PubMedPubMedCentralGoogle Scholar
  27. 27.
    Poon M, Zeng L, Zhang L, Lam H, Emmenegger U, Wong E, et al. Incidence of skeletal-related events over time from solid tumour bone metastases reported in randomised trials using bone-modifying agents. Clin Oncol (R Coll Radiol). 2013;25(7):435–44.CrossRefGoogle Scholar
  28. 28.
    Gómez García S, Clemons M, Amir E. Rethinking end-points for bone-targeted therapy in advanced cancer. Eur J Cancer. 2016;63:105–9.CrossRefGoogle Scholar
  29. 29.
    Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994;9(5):745–51.CrossRefGoogle Scholar
  30. 30.
    Tripathy D, Lichinitzer M, Lazarev A, MacLachlan SA, Apffelstaedt J, Budde M, et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol. 2004;15(5):743–50.CrossRefGoogle Scholar
  31. 31.
    Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone modifying agents in metastatic breast cancer. J Clin Oncol. 2011;29:1221–7.CrossRefGoogle Scholar
  32. 32.
    Himelstein AL, Qin R, Novotny PJ, Seisler DK, Khatcheressian JL, Roberts JD, et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. J Clin Oncol. 2015;33(15 Suppl):9501 0732–183X.Google Scholar
  33. 33.
    Hortobagyi GN, Lipton A, Chew HK, et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE-2 trial. J Clin Oncol. 2014;32(5 Suppl):LBA9500.CrossRefGoogle Scholar
  34. 34.
    Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, et al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol. 2013;14(7):663–70.CrossRefGoogle Scholar
  35. 35.
    Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48(16):3082–92.CrossRefGoogle Scholar
  36. 36.
    Amgen Canada Inc. XGEVA® product monograph. Mississauga, Ontario; 14 October 2011.Google Scholar
  37. 37.
    • Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, et al. Cost-effectiveness analysis of monthly zoledronic acid, zoledronic acid every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases: CALGB 70604 (Alliance). J Clin Oncol. 2017;35(35):3949–55 Robust cost-effectiveness analysis for different therapeutic options for bone-targeted therapy in metastatic breast cancer.CrossRefGoogle Scholar
  38. 38.
    •• Van Poznak C, Somerfield MR, Barlow WE, et al. Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline update. J Clin Oncol. 2017;35:3978 Important North American practice guideline for the use of bone-targeted therapy in metastatic breast cancer.CrossRefGoogle Scholar
  39. 39.
    Coleman R, Body JJ, Aapro M, et al. Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2014;25(Suppl 3):iii124.CrossRefGoogle Scholar
  40. 40.
    Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol. 2014;25:1871.CrossRefGoogle Scholar
  41. 41.
    Lüftner D, Lorusso V, Duran I, Hechmati G, Garzon-Rodriguez C, Ashcroft J, et al. Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational study. Springerplus. 2014;3:328.CrossRefGoogle Scholar
  42. 42.
    Hartkopf AD, Wallwiener M, Fehm TN, Hahn M, Walter CB, Gruber I, et al. Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapse. Ann Oncol. 2015;26(6):1155–60.CrossRefGoogle Scholar
  43. 43.
    Kaplan RN, Rafii S, Lyden D. Preparing the ‘soil’: the premetastatic niche. Cancer Res. 2006;66:11089–93.CrossRefGoogle Scholar
  44. 44.
    Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11:411–25.CrossRefGoogle Scholar
  45. 45.
    Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655–64.CrossRefGoogle Scholar
  46. 46.
    Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem. Biophys. Res. Commun. 2005;328:679–87.CrossRefGoogle Scholar
  47. 47.
    Russell K, Amir E, Paterson A, Josse R, Addison C, Kuchuk I, et al. Does estrogen play a role in response to adjuvant bone-targeted therapies? J Bone Oncol. 2013;2(4):167–73.CrossRefGoogle Scholar
  48. 48.
    •• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386(10001):1353–61 Individual patient meta-analysis of trials exploring bisphosphonates in early-stage breast cancer. Confirmed that benefit was seen only in postmenopausal women.CrossRefGoogle Scholar
  49. 49.
    Rathbone EJ, Brown JE, Marshall HC, Collinson M, Liversedge V, Murden GA, et al. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). J Clin Oncol. 2013;31(21):2685–91.CrossRefGoogle Scholar
  50. 50.
    Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28(8):1700–12.CrossRefGoogle Scholar
  51. 51.
    Hadji P, Coleman RE, Wilson C, Clézardin P, Aapro M, et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol. 2016;27(3):379–90.CrossRefGoogle Scholar
  52. 52.
    Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9992):433–43.CrossRefGoogle Scholar
  53. 53.
    Gnant M, Pfeiler G, Steger GG, et al. Adjuvant denosumab in early breast cancer: disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial. J Clin Oncol. 2018;36S:ASCO #500.CrossRefGoogle Scholar
  54. 54.
    Coleman RE, Finkelstein D, Barrios CH, et al. Adjuvant denosumab in early breast cancer: first results from the international multicenter randomized phase III placebo controlled D-CARE study. J Clin Oncol. 2018;36S:ASCO #501.CrossRefGoogle Scholar
  55. 55.
    Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011 Sep 7;103(17):1299–309.CrossRefGoogle Scholar
  56. 56.
    Goldvaser H, Barnes TA, Šeruga B, Cescon DW, Ocaña A, Ribnikar D, Amir E. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2018;110(1):djx141.CrossRefGoogle Scholar
  57. 57.
    Lustberg MB, Reinbolt RE, Shapiro CL. Bone health in adult cancer survivorship. J Clin Oncol. 2012;30(30):3665–74.CrossRefGoogle Scholar
  58. 58.
    Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013;24(2):398–405.CrossRefGoogle Scholar
  59. 59.
    Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 2009;9(2):77–85.CrossRefGoogle Scholar
  60. 60.
    Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, et al. Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer. 2012;12(1):40–8.CrossRefGoogle Scholar
  61. 61.
    Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337–42.CrossRefGoogle Scholar
  62. 62.
    Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153–61.CrossRefGoogle Scholar
  63. 63.
  64. 64.
    Riggs BL, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23:279–302.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Medical OncologyUniversity of Toronto and Princess Margaret Cancer CentreTorontoCanada
  2. 2.Davidoff Cancer Centre, Beilinson Hospital, Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael

Personalised recommendations